Functional Restoration against Degenerative Diseases
ICM’s AAV gene therapies are focused on degenerative diseases caused by loss-of-function related to aging and environmental factors such as inflammation and oxidative stress. We anticipate effective therapeutic solutions for incurable degenerative diseases can be established by delivering therapeutic genes restoring lost functions. We are currently developing ICM-203, a gene therapies for osteoarthritis (OA) and ICM-322, a gene therapy for age-related macular degeneration (AMD). For the lead pipeline ICM-203, Phase 1/2a clinical trial study is in progress in Australia, and FDA IND application(P1/2a) was approved in October 2022.
Correction of Inborn Mutation for Genetic Diseases
ICM also aims to provide therapeutic solutions for inborn genetic diseases caused by lack or dysfunction of certain genes from birth. Our vector design technique is an efficient tool to develop therapeutic candidates for AAV gene therapy. Also, regulatory advantages would help us develop these kinds of rare diseases having no available effective treatment.
“Broad Spectrum of ICM Pipelines for Incurable Diseases”
Pipeline
Disease
Discovery
Preclinical
Clinical
ICM-203
Osteoarthritis
ICM-502
Osteoarthritis (Canine)
ICM-322
Degenerative RD
ICM-322
Inherited RD
ICM-403
Congenital
Hearing Loss